Currently, the reference standard treatment for locally advanced rectal cancer, meaning tumours that have grown deeper into the layers of the rectal wall and/or involved nearby lymph nodes, but have not yet spread to the rest of the body – is to submit patients to chemotherapy and radiotherapy before surgery. This “total neoadjuvant therapy” reduces the risk of the cancer coming back in the rectum and can lower the risk of metastases, but has a cost for the patients because of the detrimental effects of radiation. 

Professor Parreira, Clinical Director of the Champalimaud Clinical Centre since its founding, was distinguished by the President of the Portuguese Republic, Marcelo Rebelo de Sousa, with the rank of Grand Officer of the Order of Public Instruction. The ceremony took place in Palácio de Belém on the 14th of january, 2026.

[THIS CALL IS NOW CLOSED]

Offer Description

We are looking for a Laboratory Technician to be part of the Advanced Omics Platforms (AOP) of Botton-Champalimaud Pancreatic Cancer Centre, to provide technical services to support the current operation.
 

Key Responsibilities

- Perform laboratory protocols to produce reliable and precise data to support scientific research.

- Perform routine laboratory protocols in accordance with Standard Operating Procedures (SOPs).

Host

Adriana Sánchez Danés, PhD, Cancer and Stem Cell Biology Lab

Venue

Seminar room

Abstract

In this seminar, I will present recent advances developed in our laboratory in CAR-based adoptive T-cell immunotherapy, with a particular focuss on leukemia. The talk will highlight γδ T cells as allogeneic effector platforms and explore emerging dual-targeting and armored CAR strategies.

Join us in Lisbon this October for the 3rd Botton Champalimaud International Pancreatic Cancer Conference, where leading experts from around the world will come together to shape the future of pancreatic cancer care and research.

This year's conference will focus on Locally Advanced and Metastatic Pancreatic Cancer, showcasing the latest translational discoveries, clinical breakthroughs, advanced surgical techniques, and innovative therapeutic strategies.

The Lucerne Consortium, a multidisciplinary group of European cancer societies and researchers that creates guidelines for early breast cancer care, published, in the December issue of the journal The Lancet Oncology, the conclusions of its Lucerne Toolbox 3 initiative, which pave the way to better treatment for patients in early stages of breast cancer.

The Lucerne consortium has already presented consensus recommendations for locoregional therapy after primary systemic therapy and for axillary management in early breast cancer. Now comes the turn of digital tools and AI.

With more than three decades of pioneering work in breast cancer prevention, Dr Andrea De Censi, has joined the Champalimaud Foundation as the new Director of the Breast Unit. An internationally recognised medical oncologist and a leader in chemoprevention, Dr De Censi brings a vision that integrates prevention, clinical care and translational research in a patient-centred model.